loe-exposure

Rank upcoming FDA Orange Book patent and exclusivity expiries BY the gross Medicare Part D spending exposed to them, with marketed-generic status for each ranked drug resolved from live CMS NADAC price evidence. Answers which expiries matter, not merely which come first. Reports EXPOSURE, never forecast savings. Spending is gross of manufacturer rebates. Orange Book small molecules only, so biologics — among the largest Part D line items — are excluded, and the headline total must not be read as spending that will "go generic".

{'type': 'object', 'required': [], 'properties': {'limit': {'type': 'string', 'description': 'How many drugs to rank, default 25'}, 'window': {'type': 'string', 'description': 'Months ahead to include, default 24'}}}